S
S

Siemens

News

Roche warns 2023 profits will fall on $5 bln COVID sales hit

UPDATE 3-Roche warns 2023 profits will fall on $5 bln COVID sales hit 2023 outlook weaker than expected - analysts Shares down 1.4% in early trading Co says falling demand for COVID treatments, testing will hit sales New CEO under pressure to replenish new drug pipeline Adds detail By Ludwig Burger BASEL, Feb 2 (Reuters) - Roche ROG.S warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sig
A
G
P
R
S

Siemens Gamesa posts $974 mln net loss on higher warranty costs

UPDATE 2-Siemens Gamesa posts $974 mln net loss on higher warranty costs Adds details on outlook, context By Christoph Steitz and Inti Landauro FRANKFURT/MADRID, Feb 2 (Reuters) - Beleaguered wind turbine maker Siemens Gamesa SGREN.MC , soon to be delisted and folded into parent Siemens Energy ENR1n.DE , said on Thursday its first-quarter net loss more than doubled on higher warranty provisions as a result of faulty components.
G
S

Siemens Healthineers confirms outlook despite Q1 profit drop

UPDATE 2-Siemens Healthineers confirms outlook despite Q1 profit drop Adds details, share price, CEO BERLIN, Feb 2 (Reuters) - Siemens Healthineers SHLG.DE confirmed its full-year outlook on Thursday despite a drop in quarterly profit driven by low demand in China, as it saw strong order growth in the first quarter. The company stuck with its outlook for comparable revenue to be flat within a range of a 1% fall to a 1% increase in fiscal 2023 from last year's 21.7 billion euros.
S

Siemens Healthineers Q1 profit slides on lower 19 test sales

Siemens Healthineers Q1 profit slides on lower COVID-19 test sales BERLIN, Feb 2 (Reuters) - U.S.-German medical device maker Siemens Healthineers SHLG.DE on Thursday reported a 28% drop in quarterly operating profit due to lower sales of rapid COVID-19 antigen tests and delays at a supplier of its Varian business. Adjusted earnings before interest and tax (EBIT) fell to 647 million euros ($712.93 million), less than the 663 million expected by analysts, according to a consensus provided by the
S

Perella employee probed over alleged insider trading dies -sources

UPDATE 1-Perella employee probed over alleged insider trading dies -sources Adds details, background FRANKFURT, Jan 31 (Reuters) - A London-based employee of advisory firm Perella Weinberg Partners PWP.O under investigation for alleged insider trading has died by suicide, two people with knowledge of the situation said on Tuesday. "We are incredibly saddened by the tragic loss of our colleague," Perella said in a statement, without giving details.
D
G
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.